[go: up one dir, main page]

PE20040684A1 - Derivados de bencimidazol como antagonistas de histamina h3 - Google Patents

Derivados de bencimidazol como antagonistas de histamina h3

Info

Publication number
PE20040684A1
PE20040684A1 PE2003000390A PE2003000390A PE20040684A1 PE 20040684 A1 PE20040684 A1 PE 20040684A1 PE 2003000390 A PE2003000390 A PE 2003000390A PE 2003000390 A PE2003000390 A PE 2003000390A PE 20040684 A1 PE20040684 A1 PE 20040684A1
Authority
PE
Peru
Prior art keywords
alkyl
histamine
antagonists
benzimidazole derivatives
link
Prior art date
Application number
PE2003000390A
Other languages
English (en)
Inventor
Neng-Yang Shih
Joseph A Kozlowski
Robert G Aslanian
Michael Y Berlin
Wing C Tom
Pietro Mangiaracina
Qingbei Zeng
Stuart B Rosenblum
Jianhua Cao
Mwangi W Mutahi
Christopher W Boyce
Kevin D Mccormick
Daniel M Solomon
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20040684A1 publication Critical patent/PE20040684A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE BENCIMIDAZOL DE FORMULA I DONDE LA LINEA DE PUNTOS REPRESENTA UN DOBLE ENLACE OPCIONAL, a Y b SON 0 A 2, n Y p SON 1, 2, 3; r ES 0 A 3; SIEMPRE QUE M2 ES N, p NO ES 1; Y CUANDO r es 0, M2 ES C(R3); Y QUE LA SUMA DE p Y r ES 1 A 4; M1 Y M2 SON C(R3) O N; X ES UN ENLACE o ALQUILENO C1-C6; Y ES C(O), C(S), (CH2)q, NR4C(O), C(O)NR4, ENTRE OTROS; q ES 1 A 5, CON LA CONDICION DE QUE CUANDO AMBOS M1 y M2 SON N, q ES 2 A 5; Z ES UN ENLACE ALQUILENO C1-C6, ALQUENILENO C1-C6, C(O), CH(CN), SO2 O CH2C(O)NR4; R1 ES UN RADICAL DE FORMULA a, DONDE R ES H, ALQUILO C1-C6, HALO, ALQUILO C1-C6, ENTRE OTROS; k ES 0 A 4; R25 ES ALQUILO C1-C6, HALOGENO, ENTRE OTROS; R2 ES UN ANILLO HETEROARILO DE 6 MIEMBROS CON 1 A 2 HETEROATOMOS DE N ENTRE OTROS; R3 ES HALOGENO, ALQUILO C1-C6, OH, ALCOXI C1-C6; R4 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R12 ES ALQUILO C1-C6, HIDROXILO, ALCOXILO C1-C6 O F; R13 ES ALQUILO C1-C6, OH, ALCOXI C1-C6, F. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UNO DE ESTOS COMPUESTOS Y OPCIONALMENTE UN ANTAGONISTA DE HISTAMINA H1, ESTOS COMPUESTOS SON ANTAGONISTAS DE HISTAMINA H3
PE2003000390A 2002-04-18 2003-04-16 Derivados de bencimidazol como antagonistas de histamina h3 PE20040684A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37373102P 2002-04-18 2002-04-18

Publications (1)

Publication Number Publication Date
PE20040684A1 true PE20040684A1 (es) 2004-10-05

Family

ID=29251069

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000390A PE20040684A1 (es) 2002-04-18 2003-04-16 Derivados de bencimidazol como antagonistas de histamina h3

Country Status (27)

Country Link
EP (1) EP1499316B1 (es)
JP (1) JP4384918B2 (es)
KR (1) KR100827470B1 (es)
CN (1) CN100522166C (es)
AR (1) AR040405A1 (es)
AT (1) ATE389406T1 (es)
AU (1) AU2003223627B2 (es)
BR (1) BR0309348A (es)
CA (1) CA2481940A1 (es)
CY (1) CY1110363T1 (es)
DE (1) DE60319813T2 (es)
DK (1) DK1499316T3 (es)
EC (1) ECSP045367A (es)
ES (1) ES2301791T3 (es)
HK (1) HK1067981A1 (es)
IL (1) IL164584A (es)
MX (1) MXPA04010173A (es)
NO (1) NO20045002L (es)
NZ (1) NZ535763A (es)
PE (1) PE20040684A1 (es)
PL (1) PL373889A1 (es)
PT (1) PT1499316E (es)
RU (1) RU2323935C2 (es)
SI (1) SI1499316T1 (es)
TW (1) TW200306183A (es)
WO (1) WO2003088967A1 (es)
ZA (1) ZA200407984B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2387909T3 (es) 2003-01-14 2012-10-03 Cytokinetics, Inc. Compuestos, composiciones y procedimientos de tratamiento de la insuficiencia cardiaca
PT1615909E (pt) 2003-04-23 2008-10-30 Glaxo Group Ltd Derivados de piperazina e a sua utilização para o tratamento de doenças neurológicas e psiquiátricas
MY144470A (en) 2004-06-17 2011-09-30 Cytokinetics Inc Compounds, compositions and methods
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
JPWO2006038738A1 (ja) * 2004-10-08 2008-05-15 武田薬品工業株式会社 受容体機能調節剤
WO2006078775A1 (en) * 2005-01-21 2006-07-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
JP2008546784A (ja) * 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンh3アンタゴニストとして有用なピペリジン誘導体
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
WO2007035703A1 (en) * 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
CA2623722A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Indane derivatives as mch receptor antagonists
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2007075555A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
CA2634250A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
KR20080085031A (ko) * 2006-01-13 2008-09-22 에프. 호프만-라 로슈 아게 사이클로헥실 피페라지닐 메탄온 유도체 및 히스타민 h3수용체 조절제로서의 이의 용도
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
EP2188288A1 (en) * 2007-09-11 2010-05-26 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
DK2519522T3 (en) 2009-12-30 2014-12-08 Arqule Inc SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS
AU2012272937B2 (en) 2011-06-24 2016-09-29 Arqule, Inc Substituted imidazopyridinyl-aminopyridine compounds
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
KR101127756B1 (ko) 2011-09-02 2012-03-23 한국과학기술원 Git1 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6046646B2 (ja) * 2014-01-10 2016-12-21 信越化学工業株式会社 オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法
US10595550B2 (en) * 2014-01-22 2020-03-24 Vision Pharma, Llc Therapeutic composition including carbonated solution
WO2017035114A1 (en) * 2015-08-25 2017-03-02 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as cb-1 inverse agonists
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048109B1 (es) * 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
EP0626373B1 (en) * 1993-05-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Quinazolinone derivatives
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
MXPA03002448A (es) * 2000-09-20 2003-06-19 Schering Corp Eimidazoles sustituidos como agonistas o antagonistas duales h1 y h3 de histamina.
PE20040464A1 (es) * 2002-04-18 2004-07-24 Schering Corp Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3

Also Published As

Publication number Publication date
SI1499316T1 (sl) 2008-08-31
PL373889A1 (en) 2005-09-19
WO2003088967A1 (en) 2003-10-30
EP1499316A1 (en) 2005-01-26
RU2004133764A (ru) 2005-07-20
AU2003223627A1 (en) 2003-11-03
ATE389406T1 (de) 2008-04-15
AU2003223627C1 (en) 2003-11-03
AR040405A1 (es) 2005-04-06
BR0309348A (pt) 2005-03-01
ECSP045367A (es) 2004-11-26
PT1499316E (pt) 2008-06-30
HK1067981A1 (en) 2005-04-22
JP2005529116A (ja) 2005-09-29
CA2481940A1 (en) 2003-10-30
RU2323935C2 (ru) 2008-05-10
TW200306183A (en) 2003-11-16
NZ535763A (en) 2007-06-29
JP4384918B2 (ja) 2009-12-16
IL164584A (en) 2010-12-30
KR20040099445A (ko) 2004-11-26
IL164584A0 (en) 2005-12-18
NO20045002L (no) 2005-01-18
DE60319813T2 (de) 2009-04-23
AU2003223627B2 (en) 2006-10-12
ZA200407984B (en) 2005-10-18
KR100827470B1 (ko) 2008-05-06
ES2301791T3 (es) 2008-07-01
DK1499316T3 (da) 2008-07-21
CN100522166C (zh) 2009-08-05
EP1499316B1 (en) 2008-03-19
CN1658874A (zh) 2005-08-24
DE60319813D1 (de) 2008-04-30
CY1110363T1 (el) 2012-05-23
MXPA04010173A (es) 2005-02-03

Similar Documents

Publication Publication Date Title
PE20040684A1 (es) Derivados de bencimidazol como antagonistas de histamina h3
NO20052496L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
ES2182535T3 (es) Derivados de benzo(b)tiepina-1,-dioxido, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
PT863875E (pt) Novos compostos 4-(oxialcoxifenil)-3-oxi-piperidina para o tratamento de insuficiencia cardiaca e renal
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
MY137535A (en) New pyrrolidinium derivatives
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
ATE286897T1 (de) Morpholinderivate als antagonisten an orexinrezeptoren
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
NO20050870L (no) Fosfodiesterase 4-inhibitorer, inkludert N-substituerte anilin- og difenylaminanaloger
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
TR200200795T2 (tr) 5-HT1B antagonistleri olarak piperazin türevleri
PE20001303A1 (es) Derivados de la 4-aroilpiperidina como antagonistas del receptor ccr-3
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
ATE346067T1 (de) Carbolinderivate
AR045959A1 (es) Derivados de pirazolo- e imidazo-pirimidina
NO20070565L (no) Kinolin tiazolinoner med CDK1 antiproliferativ aktivitet
ATE233754T1 (de) Diphenyl-piperidin derivate
HRP20050213A2 (en) 2,4-substituted indoles and their use as 5-ht6 modulators
PE20020603A1 (es) Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)
PE20090629A1 (es) Pirazinas y piperidinas piperazinil sustituidas como antagonistas del receptor 5-ht7
NO20054787D0 (no) Indenderivater som farmasotiske midler
UY24010A1 (es) Nuevos pirrolocarbazoles

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed